secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001558370-24-000060
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics provides 2024 pipeline update: ATRN-119 dose escalation ongoing, IND for APR-1051 expected Q1 2024
--------------------------------------------------------------------------------

- Phase 1/2a trial of ATRN-119 continues; two patients achieved stable disease at 50 mg and 200 mg doses.
- Dose-limiting toxicity period for 350 mg cohort completed; RP2D expected H2 2024.
- IND submission for next-gen WEE1 inhibitor APR-1051 being finalized; FDA clearance expected Q1 2024.
- Preclinical data for APR-1051 show improved selectivity and reduced off-target effects vs other WEE1 inhibitors.
- Company to hold investor meetings at LifeSci Partners Corporate Access Event on Jan 10, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024000060/0001558370-24-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024000060/apre-20240104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer